Chronic hepatitis B virus monoinfection at a university hospital in Zambia

Table 2 Hepatitis B virus stage and eligibility for immediate antiviral therapy among treatment-naïve Zambian adults with chronic hepatitis B virus infection n (%)

		Overall (n = 120)	Clinical diagnosis (n = 31)	Routine diagnosis1 (n = 89)	P2
HBV stage	Immune tolerant	3 (2.5)	2 (6.4)	1 (1.1)	0.16
	Immune active	14 (11.7)	4 (12.9)	10 (11.2)	0.8
	Inactive carrier	47 (35.6)	7 (20.0)	40 (41.2)	0.023
	Indeterminate	56 (46.7)	18 (58.1)	38 (42.7)	0.14
Eligibility for immediate therapy per guidelines	WHO 2015 guidelines	13 (10.8)	9 (29.0)	4 (4.5)	< 0.013
	EASL 2017 guidelines	21 (17.5)	12 (38.7)	9 (10.1)	< 0.013

¹Routine diagnosis was defined as being tested for hepatitis B surface antigen at the blood bank, antenatal care, a community screening event, or as part of a routine medical check-up;

²A χ² test was used to compare clinically and routinely HBV-diagnosed participants;

³Data with statistical significance. HBV: Hepatitis B virus; WHO: World Health Organization; EASL: European Association for Study of the Liver.